Some believe that Dr. Missling and the few Anavex employees merely sit around and patiently twiddle their thumbs, patiently (or lazily) awaiting developments of the European Medicines Agency. If so, who wrote this new patent application?
Well, as I just did, take the time to read every word of the new Anavex patent application, especially the expansive list of human pathologies blarcamesine (Anavex 2-73) is now targeted at, starting in Section IV, pages 6 and 7.
This includes a multitude of cancers. Because I have it, I was particularly interested in the listing of Waldenstrom’s macroglubulinemia (WM), an uncommon, slowly progressing but lethal B-cell lymphoma. Presently, my WM is in typical early-stage indolence; is not progressing yet. There are a number of treatments, the Bruton’s tyrosine kinase inhibitors, that successfully suppress the lymphoma for a number of years. When I need to take a BTK inhibitor drug (probably zanabrutinib), I’ll have a few years of effective suppression of the lymphoma, typically about three years. Then, by natural selection, BTKi-resistant WM oncocytes appear and the WM patient dies.
Perhaps blarcamesine will be approved and, as indicated in this patent application, it would be a new treatment therapy for my WM.
Market Data 
Markets 
